Drug Trial Radar · NCT01763164
Study Comparing the Efficacy of MEK162 Versus Dacarbazine in Unresectable or Metastatic NRAS Mutation-positive Melanoma
Last checked: Nov 19, 2026Latest source record: Mar 22, 2021 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
402
Actual
Start
Jul 12, 2013
Primary completion
Dec 1, 2015
Study completion Jun 4, 2019
Sponsor
- Lead sponsor
- PfizerPfizer (PFE)
- Sponsor type
- Industry
- First posted
- Jan 8, 2013
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Treatment
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
Two-arm, randomized, prospective, open-label, multi-center, phase III study to compare the efficacy and safety of MEK162 (45 mg BID) versus dacarbazine (1000 mg/m2 IV every 3 weeks) in patients with advanced (Stage IIIC) unresectable or metastatic (Stage IV) NRAS Q61 mutation-positive cutaneous or unknown primary melanoma. The mutation analysis will be performed at a central laboratory. Only those patients with Q61 mutation per central laboratory and meet all eligibility criteria will be randomized. A total of 393 patients will be randomized 2:1 to receive either MEK162 or dacarbazine. Patients will be stratified according to AJCC stage (IIIC, IVM1a, and IVM1b versus IVM1c), ECOG Performance status (0 versus 1) and any prior number of lines of immunotherapy (immunotherapies versus none). This study will use an Interactive Response Technology (IRT). The primary end point of the study is progression-free survival. Key secondary end point is overall survival
Conditions
- Metastatic or Unresectable Cutaneous Melanoma
Interventions
MEK162Drug
MEK162 will be administered as a fixed dose of 45 mg (3 x 15 mg tablets) BID, with a glass of water and taken with or without food.
DacarbazineDrug
Patients randomized to dacarbazine will receive an IV infusion of dacarbazine 1000 mg/m2 over the course of 1 hour on day 1 and then every three weeks.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Progression-Free Survival (PFS) by Response Evaluation Criteria in Solid Tumors (RECIST) v1.1Time frame: From the date of randomization to the date of the first documented PD or death, whichever occurred first (maximum up to 77 weeks for binimetinib arm; maximum up to 61 weeks for dacarbazine arm)
Locations
229 sites in 27 countries. Site status is shown where the registry gives one.
Highlands Oncology Group
Fayetteville, Arkansas
Highlands Oncology Group
Rogers, Arkansas
Florida Cancer Specialists
Altamonte Springs, Florida
Florida Cancer Specialists
Bonita Springs, Florida
Florida Cancer Specialists
Bradenton, Florida
Florida Cancer Specialists
Brandon, Florida
Florida Cancer Specialists
Cape Coral, Florida
Florida Cancer Specialists
Clearwater, Florida
Florida Cancer Specialists
Clearwater, Florida
Florida Cancer Specialists
Fort Myers, Florida
Florida Cancer Specialists
Fort Myers, Florida
Florida Cancer Specialists
Gainesville, Florida
Florida Cancer Specialists
Hudson, Florida
Florida Cancer Specialists
Inverness, Florida
Florida Cancer Specialists
Largo, Florida
Florida Cancer Specialists
Largo, Florida
Florida Cancer Specialists
Naples, Florida
Florida Cancer Specialists
Naples, Florida
Florida Cancer Specialists
New Port Richey, Florida
Florida Cancer Specialists
Orange City, Florida
Florida Cancer Specialists
Orlando, Florida
Florida Cancer Specialists
Port Charlotte, Florida
Florida Cancer Specialists
Sarasota, Florida
Florida Cancer Specialists
Sarasota, Florida
Florida Cancer Specialists
Spring Hill, Florida
Florida Cancer Specialists
St. Petersburg, Florida
Florida Cancer Specialists
St. Petersburg, Florida
Florida Cancer Specialists
Tampa, Florida
Florida Cancer Specialists
Tampa, Florida
Florida Cancer Specialists
Tavares, Florida
Florida Cancer Specialists
Venice, Florida
Florida Cancer Specialists
Venice, Florida
Oncology Specialists, SC
Niles, Illinois
Oncology Specialists, SC
Park Ridge, Illinois
Goshen Center For Cancer Care
Goshen, Indiana
Eastern Maine Medical Center
Bangor, Maine
Harry and Jeannette Weinberg Cancer Institute @Franklin Square
Baltimore, Maryland
Massachusetts General Hospital
Boston, Massachusetts
Brigham and Women's Hospital
Boston, Massachusetts
Dana Farber Cancer Institute
Boston, Massachusetts
Showing 40 of 229 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.